Multiparin (Heparin Sodium)

Heparin Sodium, the active ingredient in Multiparin, is an anticoagulant presented as an injectable solution for intravenous use. It is employed to prevent and treat clot formation in patients at risk of venous thromboembolism, deep vein thrombosis and during invasive procedures. GNH USA supplies Multiparin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Multiparin is an anticoagulant that acts on the coagulation cascade to prevent pathological clot formation. - Prevention and treatment of venous thromboembolism: reduces incidence of deep vein clots and pulmonary emboli in at‑risk patients. - Prophylaxis of deep vein thrombosis and pulmonary embolism: administered peri‑operatively to lower postoperative clot risk. - Anticoagulation during cardiac surgery and other invasive procedures: maintains anticoagulation to prevent intra‑operative thrombosis.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Bleeding at the injection site - Minor bruising or hematoma formation - Nausea - Transient hypotension

Serious or Rare Side Effects: - Severe hemorrhage, including intracranial bleeding - Heparin‑induced thrombocytopenia (HIT) - Allergic reactions, potentially anaphylaxis - Elevated liver enzymes or hepatic dysfunction

Careful assessment and monitoring are required when using Multiparin. - Renal impairment: monitor anti‑Xa levels and adjust therapy as clearance may be reduced. - History of bleeding disorders: evaluate risk‑benefit before initiation. - Concurrent use of other anticoagulants: increased risk of major bleeding. - Pregnancy: consider only when clearly indicated, as safety data are limited. - Surgical procedures: discontinue prior to major surgery to reduce intra‑operative bleeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Multiparin may interact with several drug classes, altering bleeding risk or anticoagulant effect.

Major Interactions (Avoid): - Direct thrombin inhibitors (e.g., dabigatran): additive anticoagulant effect. - Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding risk. - High‑dose fibrinolytics (e.g., alteplase): increased hemorrhage.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate bleeding tendencies. - SSRIs or SNRIs: potential for increased mucosal bleeding. - ACE inhibitors: may potentiate hypotensive episodes when combined with heparin.